Table 2 ToxNav® variant results across patient characteristic and initial chemotherapy dose
Standard (n = 139) | rs12132152 HFS (n = 31) | rs2612091 HFS (n = 280) | rs3918290 Critical (n = 7) | rs67376798 High(n = 9) | No-ToxNav (n = 1556) | |
|---|---|---|---|---|---|---|
Count (column %, row %) | Count (column %, row %) | Count (column %, row %) | Count (column %, row %) | Count (column %, row %) | Count (column %) | |
Result classification* | ||||||
HFS | 0 (0%) | 31 (100, 10%) | 280 (100, 90%) | 0 (0%) | 0 (0%) | NA |
High/critical toxicity | 0 (0%) | 0 (0%) | 0 (0%) | 7 (100, 44%) | 9 (100, 56%) | NA |
Standard | 139 (100, 100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | NA |
Race | ||||||
Caucasian | 91 (65, 30%) | 24 (77, 8%) | 179 (64, 59%) | 4 (57, 1%) | 6 (67, 2%) | 1079 (69%) |
Asian | 4 (3, 67%) | 0 (0, 0%) | 2 (1, 33%) | 0 (0, 0%) | 0 (0, 0%) | 28 (2%) |
African | 1 (1, 50%) | 0 (0, 0%) | 1 (0, 50%) | 0 (0, 0%) | 0 (0, 0%) | 15 (1%) |
Other/unknown | 43 (31, 28%) | 7 (23, 5%) | 98 (35, 64%) | 3 (43, 2%) | 3 (33, 2%) | 3 (0%) |
Tumour site | ||||||
Upper GI | 19 (16, 27%) | 4 (17, 6%) | 45 (19, 63%) | 1 (20, 1%) | 2 (33, 3%) | 299 (19%) |
Lower GI | 53 (45, 32%) | 8 (33, 5%) | 101 (42, 60%) | 2 (40, 1%) | 3 (50, 2%) | 724 (47%) |
Breast | 35 (30, 30%) | 8 (33, 7%) | 71 (30, 61%) | 2 (40, 2%) | 1 (17, 1%) | 382 (25%) |
Other | 10 (9, 29%) | 4 (17, 11%) | 21 (9, 60%) | 0 (0, 0%) | 0 (0, 0%) | 132 (8%) |
Initial Capecitabine dose* | ||||||
< 60% | 0 (0, 0%) | 0 (0, 0%) | 4 (2, 50%) | 2 (67, 25%) | 2 (50, 25%) | 36 (5%) |
60–80% | 7 (10, 21%) | 1 (5, 3%) | 25 (14, 74%) | 1 (33, 3%) | 0 (0, 0%) | 120 (15%) |
80–100% | 60 (90, 27%) | 19 (95, 8%) | 144 (84, 64%) | 0 (0, 0%) | 2 (50, 1%) | 630 (80%) |
Initial 5FU dose* | ||||||
< 60% | 5 (11, 45%) | 0 (0, 0%) | 2 (3, 18%) | 1 (100, 9%) | 3 (100, 27%) | 27 (5%) |
60–80% | 5 (11, 31%) | 2 (40, 13%) | 9 (14, 56%) | 0 (0, 0%) | 0 (0, 0%) | 69 (12%) |
80–100% | 34 (77, 38%) | 3 (60, 3%) | 52 (83, 58%) | 0 (0, 0%) | 0 (0, 0%) | 461 (83%) |